Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares MSCI United Kingdom (FTSE) — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while iShares MSCI United Kingdom (FTSE) trades at $46.11. The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWU | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $48.68 |
52-Week Low | $278.09 | $39.59 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EWU trades at $46.60, up 0.41% with a bullish technical signal despite mixed moving averages. The stock shows neutral oscillators and key support at $46. Recent news highlights UK market volatility from political shifts and Middle East tensions affecting the FTSE. A dividend of $0.67 is scheduled for June 2026.
Outlook remains cautious due to UK political instability and economic headwinds, though potential short-squeeze gains offer opportunity. Risks include sterling weakness and global oil price spikes, but institutional interest in undervalued UK assets may support longer-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
